News | June 21, 2023
DGCI grants Emergency Use Authorisation to Gennova mRNA Covid booster vaccine
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional protein targets
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
